Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

Separately, Maxim Group reaffirmed a “hold” rating on shares of Ritter Pharmaceuticals in a report on Wednesday, April 12th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $5.21.

Shares of Ritter Pharmaceuticals (NASDAQ RTTR) opened at 0.60 on Tuesday. The firm’s market capitalization is $8.77 million. Ritter Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $3.75. The stock’s 50 day moving average price is $0.58 and its 200-day moving average price is $1.53.

Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.24. On average, equities analysts anticipate that Ritter Pharmaceuticals will post ($1.25) earnings per share for the current fiscal year.

WARNING: “Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Stock Rating Lowered by Zacks Investment Research” was first published by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/08/ritter-pharmaceuticals-inc-nasdaqrttr-stock-rating-lowered-by-zacks-investment-research.html.

A hedge fund recently raised its stake in Ritter Pharmaceuticals stock. KCG Holdings Inc. increased its stake in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 105,409 shares of the biotechnology company’s stock after buying an additional 76,046 shares during the period. KCG Holdings Inc. owned about 0.91% of Ritter Pharmaceuticals worth $150,000 as of its most recent filing with the SEC. Institutional investors own 13.95% of the company’s stock.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.